Madrigal Solidifies Presumed NASH Lead With 52-Week Data

 
• By Joseph Haas
  
Madrigal office
Madrigal continues to build a solid data rationale behind resmetirom • Source: Madrigal Pharmaceuticals
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D